ALS Clinical Trials in Phoenix

Showing 61-68 of 68 trials

Memantine Therapy in Amyotrophic Lateral Sclerosis

NCT01020331

Tau, a protein in the cerebrospinal fluid CSF is believed to be elevated in amyotrophic lateral sclerosis (ALS) patients. The investigators believe that Tau is truly a marker of increased neuronal death from any disease process. It is been shown that Memantine can inhibit and reverse the abnormal hyperphosphorylation of Tau and therefore the investigators are looking at the efficacy of Memantine at 10 mg twice a day (BID) to see if disease progression correlates with possible changes in Tau in ALS patients based on ALS Functional Rating Scale (ALSFRS) scores.

Amyotrophic Lateral Sclerosis

Phoenix Neurological Associates, LTD20 participantsStarted Jun 2005

Phoenix, Arizona, United States

COMPLETEDPhase 311 miles

Minocycline to Treat Amyotrophic Lateral Sclerosis

NCT00047723

The purpose of this trial is to test the safety, tolerability, and effectiveness of minocycline compared to placebo in patients with amyotrophic lateral sclerosis (ALS).

Amyotrophic Lateral Sclerosis

National Institute of Neurological Disorders and Stroke (NINDS)400 participantsStarted Jan 2003

Scottsdale, Arizona, United States • Irvine, California, United States • Los Angeles, California, United States +27 more locations

PreviousPage 4 of 4

Memantine Therapy in Amyotrophic Lateral Sclerosis

Minocycline to Treat Amyotrophic Lateral Sclerosis

ALS Trials in Other Cities

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

Other Conditions in Phoenix